Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Jimin Health: The controlling shareholder plans to transfer 5% of the company's shares through an agreement at a price of 7.72 yuan per share
On April 7th, Jiming Health (603222.SH) issued an abnormal fluctuation announcement. The company’s stock price has increased by a cumulative deviation of 20% over three consecutive trading days recently. According to the relevant provisions of the “Shanghai Stock Exchange Trading Rules,” this constitutes an abnormal fluctuation in stock trading.
In response to the abnormal trading fluctuation, the company has conducted an investigation into the relevant matters. After self-examination, the company’s main business has not undergone significant changes, and the internal and external operating environments have not experienced major changes. There are no important matters that should be disclosed but have not been disclosed.
The company’s controlling shareholder, Shuangge Group, signed a share transfer agreement with Hubei Changhe No.1 Technology Partnership (Limited Partnership) on March 6, 2026. The transfer will be conducted through an agreement transfer, with Shuangge Group transferring 26,254,600 shares of unrestricted circulating shares of Jiming Health to Changhe No.1, accounting for 5% of Jiming Health’s total share capital, at a transfer price of 7.72 yuan per share.
At the same time, based on written confirmation from the company’s controlling shareholder and actual controller, apart from the matter of introducing strategic investors into its wholly-owned subsidiary, Ezhou Second Hospital Co., Ltd., Hubei Changhe Military-Civilian Innovation Medical Technology Co., Ltd., there are no other major matters involving the company, such as major asset restructuring, share issuance, significant transactions, business restructuring, equity incentives, bankruptcy reorganization, major business cooperation, or introduction of strategic investors. Additionally, after verification by the company’s board of directors, no media reports or market rumors that could significantly impact the company’s stock trading price have been found, nor are there any hot concept topics involved.
The company reminds investors that the stock price may fluctuate significantly in the short term. Investors are advised to pay attention to the risks of secondary market trading, make cautious decisions, and invest rationally. The company also urges investors to be aware of investment risks and to invest prudently.